Table 2.
Prognostic value of immune cell types in TCGA TNBC patients (univariate) (continuous).
| Cell type | OS HR | OS 95% CI | OS pvalue | OS FDR | DFS HR | DFS 95% CI | DFS pvalue | DFS FDR |
|---|---|---|---|---|---|---|---|---|
| TILs (n = 103) | 0.80 | 0.52 to 1.22 | 0.294 | NA | 0.88 | 0.60 to 1.28 | 0.494 | NA |
| CD8 T cells (n = 132) | 0.0015 | 3.7e−06 to 0.58 | 0.033 | 0.26 | 0.060 | 0.0016 to 2.22 | 0.127 | 0.67 |
| CD4 memory activated T cells (n = 132) | 0.0000063 | 1.7e−11 to 2.26 | 0.067 | 0.28 | 0.0000031 | 5.0e−11 to 0.19 | 0.024 | 0.26 |
| M1 macrophages (n = 132) | 0.00084 | 1.1e−06 to 0.65 | 0.037 | 0.26 | 0.012 | 7.7e−05 to 1.89 | 0.087 | 0.61 |
Bold: pvalue < 0.05.
TCGA: The Cancer Genome Atlas; TNBC: triple negative breast cancer; TILs: tumor infiltrating lymphocytes OS: overall survival; HR: hazard ratio; FDR: false discovery rate; DFS: disease free survival; CI: confidence interval; NA: not applicable.